Evidence map›Paper›PMID 35095931›Full record

ReviewFrontiers in immunology2021

DNA Damage Repair in Brain Tumor Immunotherapy.

Shihong Zhao, Boya Xu, Wenbin Ma, Hao Chen, Chuanlu Jiang, Jinquan Cai, Xiangqi Meng

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shihong ZhaoDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Boya XuDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Wenbin MaDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Hao ChenDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Chuanlu JiangDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Jinquan CaiDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Xiangqi MengDepartment of Neurosurgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
Second Affiliated Hospital of Harbin Medical University · CNHarbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the gradual understanding of tumor development, many tumor therapies have been invented and applied in clinical work, and immunotherapy has been widely concerned as an emerging hot topic in the last decade. It is worth noting that immunotherapy is nowadays applied under too harsh conditions, and many tumors are defined as "cold tumors" that are not sensitive to immunotherapy, and brain tumors are typical of them. However, there is much evidence that suggests a link between DNA damage repair mechanisms and immunotherapy. This may be a breakthrough for the application of immunotherapy in brain tumors. Therefore, in this review, first, we will describe the common pathways of DNA damage repair. Second, we will focus on immunotherapy and analyze the mechanisms of DNA damage repair involved in the immune process. Third, we will review biomarkers that have been or may be used to evaluate immunotherapy for brain tumors, such as TAMs, RPA, and other molecules that may provide a precursor assessment for the rational implementation of immunotherapy for brain tumors. Finally, we will discuss the rational combination of immunotherapy with other therapeutic approaches that have an impact on the DNA damage repair process in order to open new pathways for the application of immunotherapy in brain tumors, to maximize the effect of immunotherapy on DNA damage repair mechanisms, and to provide ideas and guidance for immunotherapy in brain tumors.

Indexed as

DNA DamageDNA RepairImmunotherapyAnimalsAntineoplastic Agents, ImmunologicalBiomarkers, TumorBrain NeoplasmsHumansImmunity, InnateMolecular Targeted TherapySignal TransductionTumor EscapeAntineoplastic Agents, ImmunologicalBiomarkers, Tumorbiomarkerbrain tumorcombination therapyDNA damage repairICIimmunotherapyTAMsTME

Identifiers

PMID35095931
PMCPMC8792754
OpenAlexW4206523383

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.